Altimmune, Inc. Stock News

NEW YORK , Sept. 1, 2025 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline.

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $75,000 In Altimmune To Contact Him Directly To Discuss Their Options

Altimmune, Inc.'s pemvidutide shows competitive weight loss and MASH data, but missed a key fibrosis endpoint in a recent MASH study, causing downward share price volatility. Despite setbacks, pemvidutide's dual mechanism, safety, and efficacy suggest it could compete with market leaders semaglutide and tirzepatide. Altimmune ought to have sufficient funding for a Phase 3 trial in MASH and coul...

NEW YORK, Aug. 27, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Altimmune To Contact Him Directly To Discuss Their Options If you suffered purchased or acquired securities in Altimmune between August 10, 2023 and June 25, 2025 and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-9...

NEW YORK , Aug. 26, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of the important October 6, 2025 lead plaintiff deadline. So What: If you purchased Altimmune securities you may be entitled to compensation without paym...

GAITHERSBURG, Md., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing peptide-based therapeutics for liver and cardiometabolic diseases, today announced that management will participate and be available for one-on-one meetings at the following investor conferences:

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Altimmune, Inc. (NASDAQ: ALT).